KalVista Pharmaceuticals (KALV) Asset Utilization Ratio (2015 - 2025)

KalVista Pharmaceuticals (KALV) reported Asset Utilization Ratio of 0.28 for Q3 2025, up 549.71% on a YoY basis from 0.04 in Q3 2024, and up 362.47% sequentially from 0.06 in Q2 2025.

KalVista Pharmaceuticals (KALV) Asset Utilization Ratio (2015 - 2025) Analysis & Trends

KalVista Pharmaceuticals (KALV) has 8 years of Asset Utilization Ratio data on file, last reported at 0.28 in Q3 2025.

  • For the quarter ending Q3 2025, Asset Utilization Ratio rose 549.71% year-over-year to 0.28; the trailing twelve-month figure through Jul 2025 stood at 0.28 (up 549.71% YoY), and the FY2025 full-year result was 0.05, down 81.06% from the prior year.
  • Asset Utilization Ratio improved to 0.28 in Q3 2025, from 0.06 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.28 in Q3 2025 to a low of 0.04 in Q3 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 0.69
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 0.47
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 0.37
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 KalVista Pharmaceuticals 1.36 Bn 1.36 Bn 49.41 Mn 0.28

Historic Data

Download Data
DateValue
Jul 31, 2025 0.28
Apr 30, 2025 0.06
Jul 31, 2024 0.04
Apr 30, 2020 0.13
Jan 31, 2020 0.11
Oct 31, 2019 0.12
Jul 31, 2019 0.13
Apr 30, 2019 0.13
Jan 31, 2019 0.14
Oct 31, 2018 0.17
Jul 31, 2018 0.20
Apr 30, 2018 0.13
Jan 31, 2018 0.07
Oct 31, 2017 0.05
Jul 31, 2017 0.02
Apr 30, 2017 0.04
Mar 31, 2016 0.00
Dec 31, 2015 0.00
Sep 30, 2015 0.00
Jun 30, 2015 0.00